Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

One of the most difficult issues to deal with as a cancer survivor is the positivity trap. Four and a half years ago, I was diagnosed with follicular lymphoma, a form of blood cancer that is ...

Newer-generation Bruton's tyrosine kinase (BTK) inhibitors have found a place in the management of follicular lymphoma, a ...

It’s spring, a time for new beginnings following a cancer diagnosis; however, I have an ongoing issue that I can’t dismiss.

—Most follicular lymphoma cases exhibit classic clinicopathologic and molecular features, but a range of less common histopathologic variants have been documented, confounding diagnosis and ...

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone ...

FDA Approves New Drug Combination for Mantle Cell LymphomaThe FDA has approved a new pill to treat adults with a type of blood cancer called mantle cell lymphoma (MCL). If you have follicular ...

SAN DIEGO -- The combination of loncastuximab tesirine (Zynlonta) and rituximab achieved promising response rates in patients with relapsed or refractory follicular lymphoma (R/R FL), according to ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

Researchers sought to determine whether mosunetuzumab would have long-term efficacy in patients with follicular lymphoma.

Bayer has said it plans to withdraw its PI3K inhibitor Aliqopa from the US market as a treatment for follicular lymphoma (FL) after the drug failed a confirmatory trial, dealing another blow to ...